Wednesday, October 6, 2021

SUVEN | Potential Outperformer


investment ,

Suven Life Sciences Limited

CMP 107

➽  Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. It engages in drug discovery and development of new chemical entities (NCE) in central nervous system therapies. 

The company's product candidates include SUVN-502 for the treatment of Alzheimer's disease and neuropsychiatric symptoms; SUVN-G3031, a potent and selective histamine H3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and SUVN-911, a novel, potent, and selective a42 nicotinic acetylcholine receptor antagonist for the treatment of depressive disorders.

 It is also develops SUVN-D4010, a potent, selective, and orally bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for the treatment of cognitive disorders and schizophrenia; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for the treatment of gastrointestinal disorders.

 The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is headquartered in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.

EXIDEIND | Stock Analysis & Price Outlook

  Price Levels

Make long position for the potential upside level of 148 -164 in short to mid term. Now 96 - 102 is ideal zone for buying if available. Prefer buy on dips.

CCHHL| Stock Analysis & Price Outlook

Thanks for your Precious Time.

Finvest Online
Telegram  :

Disclaimer- The information on this blog are based on my personal opinion and experience, it should not be considered professional financial investment advice and in no way it should be considered as a tip. We does not take any compensation of any kind whatsoever from any reader,user and company that are mention on this website.  Please remember that this is a blog, and you do not need to agree with anything I write.We are not SEBI registered financial advisor or analyst.

No comments:

Post a Comment